The utility of second single antigen bead assay: Clearing the water or stirring up mud?
The utility of second single antigen bead assay: Clearing the water or stirring up mud?
复制标题
DOI：
10.1016/j.humimm.2020.09.002
复制
发表时间：
2020-12
期刊：
影响因子：
2.7
通讯作者：
Bray RA
中科院分区：
文献类型：
--
作者：
Sullivan HC;Krummey SM;Gebel HM;Bray RA
虽然固相单抗原珠（SAB）检测为HLA群体和器官分配提供了重大进展，但它并非没有局限性。特别是，假阳性反应导致解释性挑战，并且如果相应的抗原被认为是不可接受的，则有可能排除移植。有两种不同的供应商平台可用于SAB测试，一种比另一种更新。本文的目的是评估在主平台产生可疑（特别是假阳性）反应的情况下使用较新的SAB平台的好处。因此，我们实验室中观察到的42份具有常见假阳性模式的血清样本使用较新的平台进行了检测。根据第二个平台与主要平台相比是否未产生反应性、相同模式或明显不同模式，将病例分别分类为已消退、等同或不同。大约33%的病例得到解决，46%等同，21%存在分歧。该项目揭示了在实验室的测试菜单中添加第二个SAB平台的优势，包括解析具有挑战性的样本，以及更广泛地覆盖不同的等位基因和独特的II类α/β亚基组合。然而，在实验室中验证、维护和计费另一种测试方法的挑战可能是常规使用的障碍。
Though solid-phase single antigen bead (SAB) testing has provided major advances to the HLA community and organ allocation, it has not been without limitations. In particular, false-positive reactions lead to interpretative challenges and the potential to preclude a transplant if the corresponding antigens are deemed unacceptable. Two different vendor platforms are commercially available for SAB testing, one more recent than the other. The aim herein was to assess the benefit of using the newer SAB platform in situations where the primary platform yielded suspicious (specifically, false positive) reactions. Therefore, 42 serum samples with commonly encountered false-positive patterns observed in our laboratory were tested with the newer platform. Cases were classified as resolved, equivalent, or divergent based on whether the second platform produced no reactivity, the same pattern, or a distinctly different pattern compared to the primary platform, respectively. Approximately 33% of cases were resolved, 46% were equivalent, and 21% were divergent. The project revealed advantages of adding a second SAB platform to the laboratory’s test menu including resolving challenging samples and including broader coverage of different alleles and unique class II alpha/beta subunit combinations. However, the challenges of validating, maintaining, and billing for another test method in the laboratory may be barriers to routine use.
登录
查看更多内容
影响因子：
6.2
作者：
Schnaidt, Martina;Weinstock, Christof;Wernet, Dorothee
通讯作者：
Wernet, Dorothee
影响因子：
6.2
作者：
Visentin, Jonathan;Guidicelli, Gwendaline;Taupin, Jean-Luc
通讯作者：
Taupin, Jean-Luc
影响因子：
8.8
作者：
Bray, R. A.;Nolen, J. D. L.;Gebel, H. M.
通讯作者：
Gebel, H. M.
影响因子：
2.3
作者：
Clerkin, Kevin J.;See, Sarah B.;Zorn, Emmanuel
通讯作者：
Zorn, Emmanuel
影响因子：
2.7
作者：
Sullivan HC;Gebel HM;Bray RA
通讯作者：
Bray RA